---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077599"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:10:02.084583+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics receives Nasdaq non-compliance notice for audit committee vacancy

## Summary
- On June 27, 2023, Nasdaq confirmed Protagonist is not compliant with Listing Rule 5605 requiring an audit committee of at least three independent directors.
- The vacancy arose after Sarah Noonberg, M.D., Ph.D. did not stand for re-election at the May 25, 2023 annual meeting.
- Company has a cure period until the earlier of its next annual meeting or May 27, 2024 to fill the audit committee seat.
- Board is in the process of identifying and selecting a new independent director to meet Nasdaq requirements.

## SEC filing metadata
- accession: 0001104659-23-077599
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923077599/0001104659-23-077599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923077599/tm2320477d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077599
- JSON: https://secwatch.observer/filing/0001104659-23-077599.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077599.txt

## Key facts
- Listing & Compliance Notices
  Protagonist Therapeutics, Inc received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4), 5605(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605, 5605(c)(4), 5605(a)(2)
  source text: June 27, 2023, the Company received a letter from Nasdaq confirming that t he Company is no longer in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605, which requires that the audit committee of a listed company be comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company intends to rely on the cure period to reestablish compliance with Nasdaq Listing Rule 5605. The cure period is generally defined as until the earlier of the Company’s next
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923077599/0001104659-23-077599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.